REG - Tern PLC - Talking Medicines CLN Modifications

TernAnnouncement

25/11/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251125:nRSY8132Ia&default-theme=true

RNS Number : 8132I  Tern PLC  25 November 2025

25 November 2025

 

Tern Plc

 

("Tern" or the "Company")

 

Talking Medicines Convertible Loan Note Modifications

 

Tern Plc (AIM:TERN), the investment company specialising in supporting high
growth, early-stage, disruptive Internet of Things ("IoT") technology
businesses, announces that the maturity dates of the approximately £0.3
million of convertible loan notes ("CLNs") that the Company holds in Talking
Medicines Limited ("Talking Medicines") have been extended, with all of Tern's
CLNs in Talking Medicines being extended to 21 November 2029.

 

A proportion of the CLNs were due to mature on 30 November 2025 and the
maturity dates of all of Talking Medicines' outstanding CLNs have now been
extended, together with the terms and conditions of the various tranches of
Talking Medicines CLNs being equalised, to reflect the CLN terms described in
Tern's announcement of 1 February 2024.  The Tern directors believe that this
will place Tern in a more advantageous negotiating position with regard to any
exit from Tern's holding in Talking Medicines.

 

Enquiries

 

 Tern Plc                                           via IFC Advisory

 Jane McCracken (Interim Non-Executive Chair)

 Allenby Capital Limited                            Tel: 0203 328 5656

 (Nominated Adviser and Broker)

 Alex Brearley / Ashur Joseph (Corporate Finance)

 Kelly Gardiner (Sales and Corporate Broking)

 IFC Advisory                                       Tel: 0203 934 6630

 (Financial PR and IR)

 Tim Metcalfe

 Graham Herring

 Florence Staton

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFEDESLEISESF



            Copyright 2019 Regulatory News Service, all rights reserved